GeoVax Labs Dividendos y recompras
Dividendo controles de criterios 0/6
GeoVax Labs no tiene historial de pago de dividendo.
Información clave
n/a
Rentabilidad por dividendo
-571.1%
Rendimiento de la recompra
| Rendimiento total para el accionista | -571.1% |
| Rendimiento futuro de los dividendos | n/a |
| Crecimiento de los dividendos | n/a |
| Próxima fecha de pago de dividendos | n/a |
| Fecha ex dividendo | n/a |
| Dividendo por acción | n/a |
| Ratio de pago | n/a |
Últimas actualizaciones de dividendos y recompras
Recent updates
GOVX: Mpox Vaccine Program Will Drive Future Upside Despite Higher Execution Risk
Analysts have reduced their price target on GeoVax Labs to $77.50 from $190.83, citing a more constrained near term outlook, limited near term catalysts, tighter capital resources, and elevated execution risk around GEO-MVA. Analyst Commentary Recent research updates point to a more cautious stance on GeoVax Labs, with price targets reset and ratings pulled back as analysts reassess execution risk and funding needs around the GEO-MVA program.GOVX: Mpox Vaccine Progress Will Support Upside Despite Hold Rating
Narrative Update Analysts have reduced their price target for GeoVax Labs by about $80. They reflect a more cautious stance as they point to a more constrained near term outlook with limited catalysts and tighter capital resources, even as the company continues to progress GEO-MVA with elevated execution risk.GOVX: Mpox Vaccine Progress Will Offset Hold Rating And Funding Constraints
Analysts have trimmed their fair value estimate for GeoVax Labs to $270.83, reflecting a slightly lower discount rate, a smaller but still very large projected revenue growth figure, and a higher profit margin assumption. They also flagged a more constrained near term outlook with limited catalysts and tighter capital resources following the recent downgrade to Hold.GOVX: Mpox Vaccine Execution Risks Will Set Up Future Upside Potential
Analysts have trimmed their price target on GeoVax Labs, with the updated fair value estimate holding at about $270.83 per share, as they flag a more constrained near term outlook, limited catalysts, and tighter capital resources around the GEO-MVA program, which they see as raising execution risk. Analyst Commentary Recent commentary points to a more cautious stance on GeoVax Labs, with the focus shifting to execution and funding rather than headline upside.GOVX: Mpox Vaccine Progress And Capital Raises Will Support Future Upside
Analysts have raised their fair value estimate for GeoVax Labs from about $204.63 to roughly $270.83, reflecting updated assumptions around discount rates, revenue growth, profit margins, and future P/E, despite a more constrained near term outlook and higher execution risk highlighted in recent research. Analyst Commentary Recent research has become more cautious on GeoVax Labs, even as fair value estimates have moved higher.GOVX: Reverse Split And Recent Capital Raises Will Support Future Upside
Analysts have kept their fair value target for GeoVax Labs steady at US$204.63, with only minor tweaks to inputs like the discount rate and expected future P/E to reflect updated modeling assumptions rather than a change in conviction. What's in the News GeoVax filed a Certificate of Amendment on January 9, 2026 to implement a 1 for 25 reverse stock split, combining every 25 existing common shares into 1 new common share, with stockholder ownership percentages and voting power described as substantially unchanged apart from rounding adjustments (company filing).GOVX: Reverse Split And Capital Raises Will Support Future Vaccine Upside
Analysts have trimmed their price target on GeoVax Labs from US$240.63 to US$204.63, citing updated assumptions for profit margins and a slightly higher discount rate, while keeping long term revenue growth expectations and future P/E views broadly aligned with prior estimates. What's in the News GeoVax Labs filed a Certificate of Amendment on January 9, 2026 to implement a 1 for 25 reverse stock split, consolidating every 25 existing common shares into one new common share while keeping stockholders' proportional ownership and voting power largely the same, aside from rounding of fractional shares (company filing).GOVX: Late Stage Vaccine Pipeline Progress Will Drive Future Upside
Analysts have lifted their price target on GeoVax Labs from US$10.38 to US$240.63, citing updated assumptions around revenue growth of 381.98%, a profit margin of 40.57% and a forward P/E of 1.94, along with a modest adjustment to the discount rate to 7.03%. What's in the News Stockholders approved a reverse stock split authorization in November 2025, allowing a ratio between 1 for 10 and 1 for 25, with the final ratio set by the board, followed by a confirmed 1 for 25 reverse split effective January 12, 2026 (Key Developments).Gedeptin And GEO-MVA Trials Will Shape Vaccine And Cancer Pipelines
Progress in vaccines and strategic partnerships could drive revenue growth from commercialization and global stockpile opportunities.We Think GeoVax Labs (NASDAQ:GOVX) Needs To Drive Business Growth Carefully
Sep 08
GeoVax: Possible Vaccine Advancements In 2 Big Indications
Aug 08GeoVax adds 16% as journal publishes animal study on ebolavirus vaccine
Jul 28Companies Like GeoVax Labs (NASDAQ:GOVX) Could Be Quite Risky
May 24GeoVax: A Legitimate COVID-19 Phase 2 Vaccine Candidate Trading At Only A $25 Million Valuation
Dec 27We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth
Nov 27GeoVax: Expands Immuno-Oncology Pipeline With Clinical-Stage Program
Oct 03We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth
Aug 14Estabilidad y crecimiento de los pagos
Obteniendo datos sobre dividendos
Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de GOVX han sido estables en el pasado.
Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de GOVX han aumentado.
Rentabilidad por dividendo vs. Mercado
| Rentabilidad por dividendo de GeoVax Labs vs. Mercado |
|---|
| Segmento | Rentabilidad por dividendo |
|---|---|
| Empresa (GOVX) | n/a |
| Suelo de mercado 25% (US) | 1.4% |
| Techo de mercado 25% (US) | 4.2% |
| Media de la industria (Biotechs) | 2.6% |
| Analista de previsiones (GOVX) (hasta 3 años) | n/a |
Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de GOVX en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.
Alto dividendo: No es posible evaluar la rentabilidad por dividendo de GOVX en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.
Pago de beneficios a los accionistas
Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de GOVX para determinar si sus pagos de dividendos están cubiertos por los beneficios.
Pago en efectivo a los accionistas
Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que GOVX no ha comunicado ningún pago.
Descubre empresas que pagan buenos dividendos
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/03 02:22 |
| Precio de las acciones al final del día | 2026/05/01 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
GeoVax Labs, Inc. está cubierta por 5 analistas. 3 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| James Molloy | Alliance Global Partners |
| null null | CG Capital |
| Jason Kolbert | D. Boral Capital LLC. |